Close
FINDING CURES TOGETHER<sup>SM</sup>

Tumor Immunology and Immunotherapy

Tuesday, Nov. 27   

Wednesday, Nov. 28

Thursday, Nov. 29

Friday, Nov. 30

Tuesday, Nov. 27 

Welcome and Keynote Lectures
5-7 p.m.

Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic micro-environment
Elizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland

Precision CAR T therapy
Carl H. June, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA


Opening Reception
7-9 p.m.


Wednesday, Nov. 28 

Continental Breakfast
7-8 a.m.


Plenary Session 1: Microbiome Influences on Cancer Development and Response to Therapy
Session Chair: Jennifer Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-10:30 a.m.

The role of the microbiome in response to cancer therapy
Jennifer Wargo

The microbiome associations of colon cancer
Cynthia L. Sears, Johns Hopkins University School of Medicine, Baltimore, Maryland

Leveraging gut microbiota networks to impact tumor immunotherapy*
Lata Jayaraman, Seres Therapeutics, Cambridge, Massachusetts

Bacteroides fragilis toxin-induced epithelial-mesenchymal transition and stem-like phenotype in breast epithelial cells and concomitantly activated Notch1 and βcatenin axes*
Sheetal Parida, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Microbiota: Key modulator of the tumor microenvironment
Romina Goldszmid, NIH, Bethesda, Maryland

Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy
Thomas Gajewski, The University of Chicago, Chicago, Illinois


Break
10:30-11 a.m.


Plenary Session 2: Tools for Discovery: Systems Biology and High Density Analytics
Session Chair: Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee
11 a.m.-1 p.m.

Hitting the target: T-cell receptors, cross reactivity, and tumors
Paul G. Thomas

Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab*
Milena Music, University of Toronto, Toronto, ON, Canada

Single-cell analysis illuminates dysfunctional CD8+ T cells as a proliferative, dynamically regulated compartment within human melanoma*
Ido Yofe, Weizmann Institute of Science, Rehovot, Israel

Learning the rules of human cancer immunity
Nir Hacohen, Broad Institute / Massachusetts General Hospital, Charlestown, Massachusetts

Using high dimensional machine assisted analysis for biomarkers detection and guidance of immunotherapy to cancer
Carsten Krieg, Medical University of South Carolina, Charleston, South Carolina


Poster Session A / Lunch
1-3:30 p.m.


Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy
Session Chair: Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
3:30-6 p.m.

Metabolic regulation of cell proliferation
Matthew G. Vander Heiden

The LXR/ApoE pathway regulates the innate immune system in cancer
Masoud Tavazoie, Rgenix, Inc., New York, New York

Collagen scavenging alters macrophage phenotype in pancreatic cancer*
Madeleine LaRue, New York University Medical Center, New York, New York

Blockage of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression*
Luis Felipe Campesato, Memorial Sloan Kettering Cancer Center, New York, New York

Fueling T cells in inflammation and cancer
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee

LC3-associated phagocytosis in inflammation and anti-cancer immunity
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, Tennessee


Dinner on Own
5:45 p.m.-


Thursday, Nov. 29

Continental Breakfast
7-8 a.m.

Plenary Session 4: Myeloid and Vascular Programs in Cancer: Key Regulators of Antitumor Immunity
Session Chair: Matthew F. Krummel, University of California San Francisco, San Francisco, California
8-10 a.m.

The key role for IRF8+ dendritic cells in cancer immunity
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Vascular reprogramming for enhancing cancer immunotherapy
Michele De Palma, Swiss Federal Institute of Technology, Lausanne, Switzerland

Targeting CD47 as a novel immunotherapy for multiple myeloma*
Jennifer Sun, Washington University in St. Louis, St. Louis, Missouri

Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy^*
Michael Klichinsky, University of Pennsylvania, Philadelphia, Pennsylvania

Imaging a world beyond checkpoints:  Classes of immune responses in cancer
Matthew F. Krummel


Break
10-10:30 a.m.


Plenary Session 5: Novel Checkpoints for Tumor Immunity Session Chair: Elizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland
10:30 a.m.-1 p.m.

Molecular mechanisms of T cell exhaustion and implications for immunotherapy
E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

The mechanistic basis of cancer immunotherapy
Ira Mellman, Cancer Immunology, Genentech, Inc., South San Francisco, California

Lymphatic vessels: Barriers to adaptive immunity in melanoma Amanda Lund, Oregon Health & Science University, Portland, Oregon

Discovery of immune regulators in primary human T cells using genome-wide CRISPR screens*
Julia Carnevale, University of California San Francisco, San Francisco, California

ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8+ T-cell response to control distal tumors*
Weiwen Deng, Aduro Biotech, Inc., Berkeley, California

Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas


Lunch on Own
1-2:30 p.m.


Plenary Session 6: New Combinations and Biomarkers
Session Chair: Sandra S. McAllister, Harvard Medical School, Boston, Massachusetts
2:30-5 p.m.

From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Pharmacological and physiological processes that affect response to immunotherapy
Sandra S. McAllister, Harvard Medical School, Boston, Massachusetts

Heterogeneous activation of multiple suppressive pathways by scRNAseq may underscore resistance to PD-1 therapy in metastatic castration-resistant prostate cancer*
Amy Moran, Oregon Health & Science University, Portland, Oregon

Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer*
Jinyang Li, University of Pennsylvania, Philadelphia, Pennsylvania

Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1
Mien-Chie Hung, The University of Texas MD Anderson Cancer Center, Houston, Texas

Understanding mechanisms for combination immunotherapy
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York


Poster Session B / Reception
5-7 p.m.


Friday, Nov. 30

Continental Breakfast
7-8 a.m.

Special Session: Novel Targets, Pathways and Tools
Session Chair: Drew Pardoll, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland

8-9:30 a.m.

Assessing in vivo mechanisms regulating the therapeutic activity of bi-specific T cell engager (BiTE®) molecules in immune-competent mice expressing a chimeric human/mouse CD3ε receptor^*
Brian Belmontes, Amgen Discovery Research, Amgen Inc., Thousand Oaks, California 

Development of chimeric forms of IFN-alpha for “on demand” in vivo cancer gene therapy*
Nadia Coltella, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study*
Lihua Budde, City of Hope National Medical Center, Duarte, California

A novel NK cell-targeted therapeutic strategy against pancreatic cancer* Kamiya Mehla, University of Nebraska Medical Center, Omaha, NE RNA aptamers specific for tumor-infiltrating myeloid cells*
Dimitri Van Simaeys, Sylvester Cancer Center, Miami, Florida

Targeted blockade of FcγRIIB on dendritic cells and macrophages enhances cellular activation and Fc-dependent immune responses*
Ryan Molony, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts

A novel immunomodulatory strategy of targeting glycol-immune checkpoints using EAGLE technology to treat cancer*
Li Peng, Palleon Pharmaceuticals, Waltham, Massachusetts (not eligible for CME credit)

Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors*
Adrian Pelin, Ottawa Hospital Research Institute, Ottawa, ON, Canada 


Break
9:30-10 a.m.


Plenary Session 7: Emerging Molecular and Cellular Targets
Session Chair: Lisa M. Coussens, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
10 a.m.-12:30 p.m.

Control of tumor immune suppression by macrophage PI3Kγ regulated pathways
Judith A. Varner, University of California San Diego, San Diego, California

A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models*
Karin Lee, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 

IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma*
Bhalchandra Mirlekar, The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Dynamic interactions between myeloid and lymphoid cells regulate response to therapy in solid tumors
Lisa M. Coussens

Tissue specific immune tolerance promotes tumor-immune escape
Niroshana Anandasabapathy, Weill Cornell Medical College, New York, New York

Repertoire and expression profiles and function of neoantigens-specific T cells
Drew M. Pardoll, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland 


Closing Remarks
12:30 p.m.



^Not eligible for CME credit



 *Short talk from proffered abstracts

Top of page